Roche (Nutley, NJ) recently announced FDA approval for its protease inhibitor Invirase (saquinavir mesylate 1000 mg) for use with ritonavir (100 mg) in combination regimens for the treatment of HIV infection. This new dosing strategy increases blood levels of saquinavir to enable twice-daily dosing and eliminates the inadequate drug levels associated with the use of Invirase alone. FDA approval for Invirase was based on data that showed that Invirase 1000 mg with ritonavir 100 mg twice daily provides similar to or greater levels of saquinavir over a 24-hour period than those achieved with another formulation of saquinavir, Fortovase, 1200 mg, 3 times per day. Invirase capsules do not require refrigeration and are smaller in size than Fortovase capsules. For more information, visit www.rocheusa.com, or call 800-526-6367.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs